3 years instead of 10: BioMarin accelerates drug development process

Yesterday, Jeffrey Cooper, Senior VP and COO of BioMarin, presented a company update at the Cowen and Company 29th Annual Health Care Conference in Boston.

In his twenty-minute talk, Jeffrey offered up a wide variety of insights about this successful pharmaceutical company.

He highlighted the fact that BioMarin has been extremely successful at getting products to the market quickly. He attributes this success to reducing overall R&D cost by minimizing time and development and starting revenues sooner. Specifically, Kuvan reached market within 3 years – while it usually takes an average 10-year process to get drug approval.

For more on Jeffrey’s update on BioMarin, and their products follow the link and click on Replay Webcast:
http://phx.corporate-ir.net/phoenix.zhtml?c=106657&p=irol-irhome